InsiderTrades

Form 4 for RAPP Rapport Therapeutics, Inc.

Accepted 2025-12-01 00:00:00 ET · period of report 2025-11-26 · accession 0001193125-25-303910 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-12-01 2025-11-26 RAPP Gault Cheryl COO M - OptEx $1.80 +5,000 176.9K +3% +$9,000
DT 2025-12-01 2025-11-26 RAPP Gault Cheryl COO S - Sale+OE $30.10 -5,000 171.9K -3% -$150.5K
DT 2025-12-01 2025-11-26 RAPP Gault Cheryl COO M - OptEx $0.00 -5,000 105.4K -5% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-11-26 M A 5,000 $1.80 176,928 D — —
2 Common Common Stock 2025-11-26 S D 5,000 $30.10 171,928 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3 Derivative Stock Option (Right to Buy) 2025-11-26 M D 5,000 $0.00 105,407 D $1.80 · — to 2033-12-05 5,000 Common Stock (F3) 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.